2022-06-20
Phase I clinical trial of IMM2902 completed the first patient enrollment and dosing in the United States.
On June 20, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-receptor fusion protein targeting human CD47xHER2(IMM2902) completed the first patient in (FPI).
View more
